Á lódáil...
Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
Safinamide (Xadago(®)) is a novel medication with both dopaminergic and non-dopaminergic effects, approved first by the European Commission and more recently by the US Food and Drug Administration (FDA) as an adjunctive treatment to carbidopa/levodopa in patients with mid- to late-stage Parkinson’s...
Na minha lista:
| Foilsithe in: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Dove Medical Press
2018
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6152599/ https://ncbi.nlm.nih.gov/pubmed/30271159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S139545 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|